CO2017004806A2 - Kit de partes para la preparación de composiciones de factor de crecimiento derivado de plaquetas recombinantes para tratar heridas - Google Patents

Kit de partes para la preparación de composiciones de factor de crecimiento derivado de plaquetas recombinantes para tratar heridas

Info

Publication number
CO2017004806A2
CO2017004806A2 CONC2017/0004806A CO2017004806A CO2017004806A2 CO 2017004806 A2 CO2017004806 A2 CO 2017004806A2 CO 2017004806 A CO2017004806 A CO 2017004806A CO 2017004806 A2 CO2017004806 A2 CO 2017004806A2
Authority
CO
Colombia
Prior art keywords
treating wounds
growth factor
derived growth
kit
preparation
Prior art date
Application number
CONC2017/0004806A
Other languages
English (en)
Inventor
Samuel Lynch
Leslie Wisner-Lynch
Original Assignee
Samuel Lynch
Wisner Lynch Leslie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel Lynch, Wisner Lynch Leslie filed Critical Samuel Lynch
Publication of CO2017004806A2 publication Critical patent/CO2017004806A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0033—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0095—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Composite Materials (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen composiciones novedosas para tratar heridas y promover la sanación de las mismas, incluyendo la composición que contiene combinaciones novedosas de un portador y el factor de crecimiento derivado de plaquetas recombinantes que tienen algunas isoformas y bioestabilidad mejorada. Los métodos para tratar heridas con la composición terapéutica novedosa usando procedimiento de dosificación que conducen a los resultados efectivos con un número mínimo de aplicaciones de tratamiento también se describen.
CONC2017/0004806A 2014-10-14 2017-05-12 Kit de partes para la preparación de composiciones de factor de crecimiento derivado de plaquetas recombinantes para tratar heridas CO2017004806A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462063793P 2014-10-14 2014-10-14
PCT/US2015/055522 WO2016061219A1 (en) 2014-10-14 2015-10-14 Compositions for treating wounds

Publications (1)

Publication Number Publication Date
CO2017004806A2 true CO2017004806A2 (es) 2017-08-18

Family

ID=55747267

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0004806A CO2017004806A2 (es) 2014-10-14 2017-05-12 Kit de partes para la preparación de composiciones de factor de crecimiento derivado de plaquetas recombinantes para tratar heridas

Country Status (10)

Country Link
US (6) US10071182B2 (es)
EP (1) EP3206670A4 (es)
JP (2) JP6871855B2 (es)
CN (1) CN107106492B (es)
AU (1) AU2015332556B2 (es)
BR (1) BR112017007645B1 (es)
CA (1) CA2962954A1 (es)
CO (1) CO2017004806A2 (es)
MX (1) MX2017004520A (es)
WO (1) WO2016061219A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2664229T3 (es) * 2006-06-30 2018-04-18 Biomimetic Therapeutics, Llc Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador
EP3206670A4 (en) 2014-10-14 2018-06-20 Samuel Lynch Compositions for treating wounds
US11083459B2 (en) * 2019-05-17 2021-08-10 Katerina Grigoropoulos Apical surgical wound debridement
US20210046163A1 (en) * 2019-08-12 2021-02-18 Bioregentech, Inc. Therapeutic systems, devices, and compositions with wound healing and tissue regenerative properties, uses thereof, and corresponding methods
CA3227151A1 (en) * 2021-07-21 2023-01-26 Organogenesis Inc. Porcine collagen compositions and methods of use thereof

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA544480A (en) 1957-08-06 J. Miller Loren Acid-resistant asphaltic composition containing organic fibers
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5498600A (en) 1984-10-12 1996-03-12 Zymogenetics, Inc. Biologically active mosaic proteins
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4769328A (en) 1984-10-12 1988-09-06 Zymogenetics Inc. Expression of biologically active PDGF analogs in yeast
US5187263A (en) 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
EP0487116B1 (en) 1984-10-12 1999-12-29 ZymoGenetics, Inc. Biologically active PDGF analogs in eucaryotic cells
US4889919A (en) 1986-08-13 1989-12-26 Zymogenetics, Inc. Biologically active PDGF derived A-chain homodimers
US5045633A (en) 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5516896A (en) 1985-02-25 1996-05-14 Zymogenetics, Inc. Biologically active B-chain homodimers
US5474982A (en) 1986-08-13 1995-12-12 Zymogenetics, Inc. PDGF analogs and methods of use
ATE131532T1 (de) * 1986-08-13 1995-12-15 Zymogenetics Inc Expression von biologisch-aktiven pdgf-analogen in eukaryotischen zellen
AU641816B2 (en) 1986-08-13 1993-09-30 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5124316A (en) 1986-11-14 1992-06-23 President And Fellows Of Harvard College Method for periodontal regeneration
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US5019559A (en) 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
JPH01500199A (ja) 1986-11-14 1989-01-26 インスティチュート・オブ・モレキュラー・バイオロジー・インコーポレーテッド 創傷の治癒および骨の再生
US5219759A (en) 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
US5705485A (en) 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US4874746A (en) 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
US5094941A (en) 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5256644A (en) 1988-05-20 1993-10-26 Institute Of Molecular Biology, Inc. Wound healing using IGF-II and TGF
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
US5034375A (en) 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US5142750A (en) 1989-01-31 1992-09-01 Johnson & Johnson Medical, Inc. Absorbent wound dressing
US5062418A (en) 1989-01-31 1991-11-05 Johnson & Johnson Medical, Inc. Napped nonwoven fabric having high bulk and absorbency
US5035887A (en) 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
DE3931803C1 (es) 1989-09-23 1990-05-10 Johnson & Johnson Medical Gmbh, 2000 Norderstedt, De
TW199858B (es) 1990-03-30 1993-02-11 Fujirebio Kk
EP0479799B1 (en) 1990-04-10 1997-08-06 Institute Of Molecular Biology Inc. Wound healing
DE69133087T2 (de) 1990-05-30 2003-04-03 Inst Molecular Biology Inc Kombination aus IGF-I und TGF-beta zur Knochenregenerierung
ES2055611T3 (es) 1990-07-23 1994-08-16 Zymogenetics Inc Pdgf resistente a proteasas y metodos de uso.
NL9002540A (nl) 1990-11-21 1992-06-16 Leer Koninklijke Emballage Lage temperatuur susceptor.
GB9102089D0 (en) 1991-01-31 1991-03-13 Johnson & Johnson Medical Net wound dressings
US5149691A (en) 1991-03-12 1992-09-22 Creative Biomolecules, Inc. Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone
JP3254013B2 (ja) 1991-09-10 2002-02-04 ジョンソン・アンド・ジョンソン・メディカル・インコーポレイテッド 包帯材料およびその製造方法
AU3062392A (en) 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
GB9123707D0 (en) 1991-11-07 1992-01-02 Johnson & Johnson Medical Ltd Polyurethane foam
GB9123708D0 (en) 1991-11-07 1992-01-02 Johnson & Johnson Medical Ltd Method of making polyurethane foam
WO1993010806A1 (en) 1991-11-25 1993-06-10 Institute Of Molecular Biology, Inc. Medicament for promoting growth of mammalian nerve
JPH07504160A (ja) 1991-11-27 1995-05-11 インスティチュート　オブ　モレキュラー　バイオロジー　インク 骨の再生
GB9206508D0 (en) 1992-03-25 1992-05-06 Jevco Ltd Biopolymer composites
GB9206509D0 (en) 1992-03-25 1992-05-06 Jevco Ltd Heteromorphic sponges containing active agents
GB9209327D0 (en) 1992-04-30 1992-06-17 Johnson & Johnson Medical Freeze-dried pad
IL105529A0 (en) * 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins
GB9212303D0 (en) 1992-06-10 1992-07-22 Johnson & Johnson Medical Ltd Absorbent products
IL106159A0 (en) 1992-06-30 1993-10-20 Dow Chemical Co Targeted delivery of growth factors for bone regeneration
US6326410B1 (en) 1992-11-04 2001-12-04 Johnson & Johnson Medical, Inc. Wound dressing comprising polyurethane foam
GB2272645B8 (en) 1992-11-23 2010-02-10 Johnson & Johnson Medical Wound dressing
GB2275686B (en) 1993-03-03 1997-04-30 Johnson & Johnson Medical Swellable wound dressing materials
US5660857A (en) 1993-03-22 1997-08-26 Johnson & Johnson Medical Inc. Biopolymer composites
GB2280850B (en) 1993-07-28 1997-07-30 Johnson & Johnson Medical Absorbable composite materials for use in the treatment of periodontal disease
GB2276819B (en) 1993-03-23 1996-12-11 Johnson & Johnson Medical Aqueous wound treatment composition comprising a polysaccharide and hexylene glycol
KR960701648A (ko) 1993-03-29 1996-03-28 마크 제이. 머레이 Pdgf와 비타민 d를 함유하는 조골세포 성장 자극 조성물(oesteoblast growth stimulating compostion containing pdgf and vitamind)
GB2281274B (en) 1993-08-31 1997-04-09 Johnson & Johnson Medical Wound dressing package
GB2281861B (en) 1993-09-21 1997-08-20 Johnson & Johnson Medical Bioabsorbable wound implant materials containing microspheres
AU8017594A (en) 1993-10-29 1995-05-22 Institute Of Molecular Biology, Inc. Osteocalcin as a marker of periodontal and peri-implant disease activity
US5656605A (en) 1994-01-26 1997-08-12 Institute Of Molecular Biology, Inc. Device to promote drug-induced nerve regeneration
US5516699A (en) 1994-02-16 1996-05-14 Institute Of Molecular Biology, Inc. Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity
AU2297395A (en) 1994-04-20 1995-11-16 Institute Of Molecular Biology, Inc. Administration of platelet-derived growth factor and bone seeking drugs for osteoporosis and bone regeneration
GB2291348B (en) 1994-07-18 1999-01-20 Johnson & Johnson Medical Sterile gel composition for wound treatment comprising alginate and polyhydric alcohol
GB2301362B (en) 1995-05-30 1999-01-06 Johnson & Johnson Medical Absorbable implant materials having controlled porosity
US20030105007A1 (en) * 1995-06-07 2003-06-05 Andre Beaulieu PDGF-betabeta and fibronectin combined in a solid wound dressing for the treatment of wounds
DK1486565T3 (da) 1995-10-11 2008-03-10 Novartis Vaccines & Diagnostic Kombination af PDGF, KGF, IGF og IGFBP til sårheling
US6309661B1 (en) 1996-02-28 2001-10-30 Carla A. Haynes Solid polysaccharide materials for use as wound dressings
GB2311027B (en) 1996-03-15 1999-10-27 Johnson & Johnson Medical Coated bioabsorbable beads for wound treatment
US5747273A (en) 1996-05-07 1998-05-05 Diagnostic Systems Laboratories, Inc. Immunoassay of total insulin-like growth factor binding protein-1
GB2318577B (en) 1996-10-28 2000-02-02 Johnson & Johnson Medical Solvent dried polysaccharide sponges
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
ES2306462T3 (es) * 1996-12-13 2008-11-01 Novartis Vaccines And Diagnostics, Inc. Analisis y separacion de proteinas del factor de crecimiento derivadas de plaquetas.
GB2320431B (en) 1996-12-20 2000-08-30 Johnson & Johnson Medical Compositions for the treatment of chronic wounds
GB2321191B (en) 1997-01-17 2000-09-27 Johnson & Johnson Medical Peptides for use in wound treatment
JP3334558B2 (ja) 1997-04-23 2002-10-15 富士レビオ株式会社 酵素免疫測定方法及び試験片
GB2324732B (en) 1997-05-02 2001-09-26 Johnson & Johnson Medical Absorbent wound dressings
AU740715B2 (en) 1997-05-08 2001-11-15 Ethicon Inc. Bandage compression indicator
US5912114A (en) 1997-09-12 1999-06-15 Johnson & Johnson Medical, Inc. Wound diagnosis by quantitating cortisol in wound fluids
US6440940B1 (en) 1997-12-18 2002-08-27 Peter J. Doyle Bioresorbable alginate derivatives
US6933326B1 (en) 1998-06-19 2005-08-23 Lifecell Coporation Particulate acellular tissue matrix
US6293950B1 (en) 1999-01-15 2001-09-25 Luitpold Pharmaceuticals, Inc. Resorbable pin systems
GB9903097D0 (en) 1999-02-11 1999-03-31 Johnson & Johnson Medical Ltd Poyurethane foams for use in wound dressings
US6979670B1 (en) 1999-03-10 2005-12-27 Biora Bioex Ab Matrix protein compositions for grafting
GB2348136B (en) 1999-03-24 2003-06-04 Johnson & Johnson Medical Ltd Wound dressings having low adherency
US6333029B1 (en) 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
US6306424B1 (en) 1999-06-30 2001-10-23 Ethicon, Inc. Foam composite for the repair or regeneration of tissue
US6283905B1 (en) 1999-08-31 2001-09-04 Ethicon System and method for producing folded articles
US6385946B1 (en) 1999-08-31 2002-05-14 Ethicon System and method for producing folded articles
US6425547B1 (en) 1999-08-31 2002-07-30 Ethicon System and method for producing coreless fabric rolls
US6915950B1 (en) 1999-10-26 2005-07-12 Johnson & Johnson Medical Device and method for chronic wound condition treatment
US7192604B2 (en) 2000-12-22 2007-03-20 Ethicon, Inc. Implantable biodegradable devices for musculoskeletal repair or regeneration
CN1827766B (zh) 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
US8025896B2 (en) 2001-07-16 2011-09-27 Depuy Products, Inc. Porous extracellular matrix scaffold and method
WO2003068802A2 (en) 2002-02-11 2003-08-21 Zymogenetics, Inc. Materials and methods for preparing dimeric growth factors
US7005136B2 (en) 2002-03-29 2006-02-28 Ethicon, Inc. Bone replacement materials utilizing bioabsorbable liquid polymers
GB2394418B (en) 2002-10-25 2007-01-31 Johnson & Johnson Medical Ltd Fluid wound dressing
DE602004015589D1 (de) 2003-04-28 2008-09-18 Johnson & Johnson Medical Ltd Schmerz-empfindliche therapeutische wundverbände
JP4950660B2 (ja) 2003-06-27 2012-06-13 エチコン、インコーポレイテッド 分娩後由来細胞を使用する眼組織の修復および再生
US7163920B2 (en) 2003-09-30 2007-01-16 Ethicon, Inc. Peptide with osteogenic activity
US7316822B2 (en) 2003-11-26 2008-01-08 Ethicon, Inc. Conformable tissue repair implant capable of injection delivery
ES2403357T3 (es) 2003-12-11 2013-05-17 Isto Technologies Inc. Sistema de cartílago particulado
WO2005077973A1 (en) 2004-02-11 2005-08-25 Virchow Biotech Private Limited Purification of recombinant human proteins
WO2005077402A1 (en) 2004-02-11 2005-08-25 Virchow Biotech Private Limited Honey based gel formulations
JP2007526807A (ja) 2004-02-23 2007-09-20 エシコン・インコーポレイテッド 診断テスト装置
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US8114841B2 (en) 2004-10-14 2012-02-14 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
US8293710B2 (en) * 2005-01-03 2012-10-23 Blue Blood Biotech Corp. Method for treating wounds using an EGF-like domain of thrombomodulin
US7238828B2 (en) 2005-03-24 2007-07-03 Ethicon, Inc. Absorbable α-cyanoacrylate compositions
WO2007013100A1 (en) 2005-07-26 2007-02-01 Virchow Biotech Private Limited Gel formulation comprising platelet derived growth factor
CA2641860C (en) 2006-02-09 2015-07-14 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
ES2664229T3 (es) 2006-06-30 2018-04-18 Biomimetic Therapeutics, Llc Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
EP3181157B1 (en) 2006-11-03 2019-08-14 BioMimetic Therapeutics, LLC Compositions and methods for arthrodetic procedures
US8709464B2 (en) * 2007-01-10 2014-04-29 The Regents Of The University Of Michigan Porous objects having immobilized encapsulated biomolecules
CA2678875A1 (en) 2007-02-20 2008-08-28 Biomimetic Therapeutics, Inc. Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw
WO2008106625A2 (en) * 2007-02-28 2008-09-04 University Of Notre Dame Du Lac Porous composite biomaterials and related methods
NZ554915A (en) 2007-05-02 2009-05-31 Quinspread Technologies Ltd Apparatus to grind, wet and impel particulate from chamber, typically for fertilizer spreading
CN106110299A (zh) 2007-06-04 2016-11-16 生物模拟治疗公司 用于治疗脊柱的组合物和方法
US20110171607A1 (en) 2007-10-25 2011-07-14 The Trustees Of Columbia University In The City Of New York Biopulp
CN105854074B (zh) 2008-02-07 2019-10-15 生物模拟治疗有限责任公司 用于牵引成骨术的组合物和方法
WO2009146456A1 (en) * 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
US20110091515A1 (en) 2008-06-12 2011-04-21 Ramot At Tel-Aviv University Ltd. Drug-eluting medical devices
AU2009291828C1 (en) 2008-09-09 2016-03-17 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
CN102316890A (zh) 2008-12-19 2012-01-11 生物模拟治疗公司 具有降低的蛋白酶活性的骨移植物以及选择和使用的方法
EP2403514A4 (en) 2009-03-05 2012-11-14 Biomimetic Therapeutics Inc Platelet-derived growth factor compositions and methods of treating osteocartilaginous defects
US8492335B2 (en) 2010-02-22 2013-07-23 Biomimetic Therapeutics, Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US20110245929A1 (en) 2010-03-05 2011-10-06 Advanced BioHealing Inc. Methods and compositions for joint healing and repair
WO2012045086A1 (en) 2010-10-01 2012-04-05 The Trustees Of Columbia University In The City Of New York Pdgf induced cell homing
US20140308332A1 (en) 2010-12-13 2014-10-16 Biomimetic Therapeutics, Llc Compositions and Methods for Spine Fusion Procedures
WO2013062994A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating full thickness burn injuries
WO2013062995A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating deep partial and full thickness wounds and injuries
CA2885721A1 (en) 2012-07-11 2014-01-16 Biomimetic Therapeutics, Llc Cell-based assay for neutralizing antibodies
EP3206670A4 (en) 2014-10-14 2018-06-20 Samuel Lynch Compositions for treating wounds

Also Published As

Publication number Publication date
AU2015332556B2 (en) 2021-04-29
US20190125926A1 (en) 2019-05-02
JP2021106935A (ja) 2021-07-29
EP3206670A4 (en) 2018-06-20
MX2017004520A (es) 2018-03-15
US10071182B2 (en) 2018-09-11
US20230372579A1 (en) 2023-11-23
AU2015332556A1 (en) 2017-04-13
US20200164102A1 (en) 2020-05-28
US20170021054A1 (en) 2017-01-26
BR112017007645A2 (pt) 2018-06-19
BR112017007645B1 (pt) 2023-05-02
JP2017532346A (ja) 2017-11-02
CN107106492B (zh) 2022-07-05
EP3206670A1 (en) 2017-08-23
CN107106492A (zh) 2017-08-29
US20210121601A1 (en) 2021-04-29
WO2016061219A1 (en) 2016-04-21
JP6871855B2 (ja) 2021-05-19
US11826486B2 (en) 2023-11-28
US20170014483A1 (en) 2017-01-19
CA2962954A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
CO2017004806A2 (es) Kit de partes para la preparación de composiciones de factor de crecimiento derivado de plaquetas recombinantes para tratar heridas
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
CO2019004945A2 (es) Inhibidores de la magl
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
CR20150067A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
UY36405A (es) Formulaciones reguladoras/bioestimulantes del crecimiento de las plantas y de los cultivos y métodos para usarlas
CR20150070A (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CL2019002583A1 (es) Inhibidores duales de magl y faah.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
EA201891439A1 (ru) Трициклические соединения и их композиции в качестве ингибиторов киназ
EA201792085A1 (ru) Смешанные дисульфидные конъюгаты тиенопиридиновых соединений и их применение